Paediatric

Acute osteoarticular infection, including septic arthritis and acute osteomyelitis

Warning
  • Consult paediatric ID for all cases.
  • Review antibiotic choice once microbiology results available.
  • Initial oral therapy should be considered for all patients unless complex or features of high risk disease (see below).
  • A review should be undertaken at 48-72 hours to ensure pain improvement, decreasing inflammatory markers and resolution of fever. IV to oral switch should be considered at that stage, if patient not already on oral antibiotics.
  • For complex or high risk disease (i.e. multifocal site, significant bone destruction, significant immunosuppression, significant soft tissue infection, sepsis/shock or less than 3 months of age), initial antibiotics should be administered IV, often for a longer duration (i.e. Up to 2 weeks)

Typical duration of therapy for respective indications:

Septic Arthritis: 10-14 days

Osteomyelitis: 3-4 weeks (may require up to 6 weeks if complex infection)

Pyomyositis: 2-3 weeks

Discitis: 4 weeks

Preferred including penicillin (non-severe) allergy

cefalexin po see dosing table below

If high risk/complex disease or unable to tolerate orals: cefazolin 50mg/kg (Max 2g) iv TDS 

  • Oral switch at 48-72 hours if clinical and biochemical improvement: Switch to cefalexin po tds (see dosing table below)
  • If unable to switch to oral therapy: Ambulate with ceftriaxone 80mg/kg (Max 4g) iv OD (if over 1 month old)

cefalexin oral dosing table:

Weight

cefalexin oral dosing

Less than 15 kg

33 mg/kg po TDS

15 to 20 kg

500mg po TDS

21 to 30 kg

750mg po TDS

31 to 40 kg

1g po TDS

Over 40 kg

1g po QDS


For penicillin allergy (severe) or MRSA patients

co-trimoxazole 27 mg/kg (Max 1.44g) iv BD

Oral switch at 48-72 hours if clinical and biochemical improvement: Switch to oral co-trimoxazole (see dosing table below) if susceptibilities allow:

Age

co-trimoxazole oral dose

6 Weeks to 5 years

24mg/kg BD

6 Years to 11 years

24mg/kg (max 960mg) BD

12 years to 17 years

960mg BD

 

Editorial Information

Last reviewed: 18 Sept 2025

Next review date: 03 Sept 2028

Author(s): AMST.

Approved By: MMTC